Products Vedolizumab was approved in many countries in 2015 as a powder for a concentrate for the preparation of an infusion solution (Entyvio). In 2020, a prefilled pen and prefilled syringe were also registered. Structure and properties Vedolizumab is a humanized IgG1 monoclonal antibody with a molecular mass of 147 kDa. Effects Vedolizumab (ATC L04AA33) … Vedolizumab
Products Natalizumab is commercially available as a concentrate for the preparation of an infusion solution (Tysabri). It has been approved in many countries since 2007. Structure and properties Natalizumab is a recombinant and humanized IgG4ϰ antibody produced in mouse cells that binds to α4-integrins. Effects Natalizumab (ATC L04AA23) has selective immunosuppressive properties. The effects are … Natalizumab
Symptoms Crohn’s disease manifests as inflammation that occurs primarily in the lower portion of the small intestine and in the colon. The typical course is chronically recurrent, meaning periods of quiescence are interrupted by episodes of disease. Common symptoms include: Abdominal pain (more likely on the right side) Nausea, vomiting Diarrhea, constipation Flatulence Fever Weight … Crohn’s Disease Causes and Treatment
Products Lifitegrast was approved in the United States in 2016 and in many countries in December 2018 as single-dose eye drops (Xiidra, pronounced Saidra in English). Structure and properties Lifitegrast (C29H24Cl2N2O7S, Mr = 615.5 g/mol) is a tetrahydroisoquinoline derivative. It exists as a white powder that is soluble in water. Effects Lifitegrast (ATC S01XA25) has … Lifitegrast
